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Bonemorphogenetic proteins (BMPs) are members of the transforming growth factor-b (TGF-b) fam-
ily that signal via type I and type II serine/threonine kinase receptors and intracellular Smad tran-
scription factors. BMPs are multifunctional regulators of development and tissue homeostasis and
they were initially characterized as inducers of bone regeneration. Genetic studies in humans and
mice showed that perturbations in BMP signaling lead to various diseases, such as skeletal diseases,
vascular diseases and cancer. Mutations in BMP type II receptor and BMP type I receptor/activin
receptor-like kinase 1 have been linked to pulmonary arterial hypertension and hereditary hemor-
rhagic telangiectasia, respectively. BMPs have also been implicated in promoting vascular calciﬁca-
tion and tumor angiogenesis. In this review we discuss the role of BMP signaling in vascular diseases
and the value of BMP signaling as a vascular disease marker or a therapeutic target.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Bone morphogenetic proteins (BMPs) are members of the
transforming growth factor-b (TGF-b) family, which also includes
TGF-bs, growth and differentiation factors (GDFs), anti-mülleriancal Societies. Published by Elsevier
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.hormone (AMH), activins and nodal. BMPs were ﬁrst identiﬁed as
potent inducers of ectopic bone formation when implanted subcu-
taneously in rats [1,2]. Subsequent studies demonstrated that
BMPs, as is the case for other TGF-b family members, are multifunc-
tional regulators in development that regulate cell proliferation,
differentiation, and apoptosis in different tissues [3,4]. BMPs exert
their signals via type I and type II transmembrane serine/threonine
kinase receptors. Inside the cell, Smad proteins play an important
role in the transduction of the signal from the active receptor
complex to the nucleus. Interestingly, misregulated BMP signaling
has been shown to be involved in the pathogenesis of skeletal and
(cardio) vascular disorders as well as cancer. Despite the recent ad-
vances in therapeutic interventions, cardiovascular disease remains
the largest health problem worldwide causing morbidity and mor-
tality. This review will focus on the role of BMP signaling in the
pathology of vascular diseases and potential clinical applications.
2. BMPs
Among the 33 members of the TGF-b superfamily, over 20 mol-
ecules form the BMP subfamily. The BMP subfamily can be further
subdivided into several subgroups, including BMP-2/4, BMP-5/6/7/
8, GDF-5/6/7 and BMP-9/10 [4,5]. BMPs are synthesized as large
precursor proteins consisting of an amino (N)-terminal signal pep-
tide, a prodomain for folding and secretion, and a bioactive carboxy
(C)-terminal mature peptide. BMP precursor proteins are producedB.V. Open access under CC BY-NC-ND license.
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cleaved by serine endoproteases (e.g. BMP-4 is cleaved by furin,
PC6 and PC7 [6]) to generate N-terminal and C-terminal fragments,
of which the latter is capable of binding to its receptor [7].
Whereas the secretion of BMPs in a latent inactive form is not
common [7], TGF-b is secreted as a latent form in which the
N-terminal remnant, also known as latency associated peptide
(LAP), sequesters and prevents the bioactive mature part from
binding to its receptors. This complex is also associated with
the latent TGF-b binding proteins (LTBP). Thus, proteolytic cleav-
age of latent TGF-b by different activators is required for the
release of the mature, active TGF-b [8].
BMP activity is also regulated by several intracellular and extra-
cellular modulators (Fig. 1). A large number of extracellular soluble
antagonists bind BMPs and block their interaction with signaling
receptors, thus dampening BMP signaling [9]. These antagonists
can be divided into three subgroups based on their structure simi-
larity: the CAN (Cerberus/DAN) family, twisted gastrulation, chor-
din and noggin. The CAN family includes gremlin and cerberus,
differential screening-selected gene aberrative in neuroblastoma
(DAN), protein related to DAN and cerberus (PRDC), coco, uterine
sensitization-associated gene-1 (USAG-1) and sclerostin [10].
Several additional BMP regulators have been identiﬁed, such as
cross-veinless 2 [CV2, also referred to as BMP endothelial cell pre-
cursor derived regulator (BMPER)], matrix GLA protein (MGP) and
neogenin [11–14]. MGP is a small, carboxyglutamic acid modiﬁedBMPs
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Fig. 1. Schematic overview of the BMP signaling pathway. BMPs interaction with surface
receptors. This activity is regulated by extracellular regulators and type III recepto
phosphorylate Smad1/5/8 (R-Smads) to propagate the signal into the cell. Smad1/5/8 fo
where, by interacting with other transcription factors, they regulate target gene exp
activation of R-Smads. Besides Smad-depend signaling, non-Smad pathways are involve
through their downstream effectors molecules. Activated MAPKs can translocate to th
response factor (SRF), ternary complex factor (TCF) family members, activator protein 1 (A
gene transcription.protein, which can bind and inhibit BMP-2 and BMP-4 by direct
protein interaction [12,15,16]. It is highly expressed in kidneys
and lungs, where excessive MGP in MGP-transgenic mice altered
pulmonary BMP-4 distribution and resulted in signiﬁcant morpho-
logical defects in the pulmonary artery tree [17]. Neogenin was
identiﬁed as a receptor for netrins and proteins of the repulsive
guidance molecule (RGM) family. The interaction of netrins-neoge-
nin or RGM-neogenin stimulated or repelled neuronal axon guid-
ance depending on the developmental context [18,19]. Recent
research suggested that neogenin is a regulator of BMP signaling
during chondrogenesis and skeletal development, since there is re-
duced expression levels of BMP target genes and intracellular BMP
signaling mediators in chondrocytes from neogenin mutant mice,
and the neogenin-deﬁcient mice is retarded in digit/limb develop-
ment and endochondral ossiﬁcation [13]. However, others reported
that neogenin acts as a repressor of BMP signaling and knockdown
of neogenin in C2C12 cells leads to increased BMP-2-induced phos-
phorylation of Smad1, Smad5, and Smad8 and osteoblast differenti-
ation [14]. The expression pattern of BMP antagonists is important
for embryonic development, as an aberrant expression pattern can
lead to defects in bone, limb and kidney formation [20].
3. BMP receptors
Like other members of the TGF-b family, BMPs bind to two
types of serine-threonine kinase receptors, known as type I andSmad1/5/8
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receptors induces heteromeric complex formation between speciﬁc type II and type I
rs/co-receptors. After being activated by type II receptors, the type I receptors
rm heteromeric complexes with Smad4 (Co-Smad) and translocate to the nucleus
ression (canonical Smad signaling pathway). I-Smads (Smad6/7) inhibit receptor
d. Activated MAPKs can regulate R-Smad activation by a direct phosphorylation or
e nucleus to phosphorylate a number of transcription factors (TF), such as serum
P1) complexes and activating transcription factor 2 (ATF2), thereby changing target
J. Cai et al. / FEBS Letters 586 (2012) 1993–2002 1995type II receptors [21,22] (Fig. 1). Both receptors share a similar
structure and are comprised of a short extracellular domain, a sin-
gle transmembrane domain and an intracellular domain with ser-
ine-threonine kinase activity. The afﬁnity of BMPs for type I
receptors is higher than for type II receptors and its afﬁnity is in-
creased by the formation of a heterotetrameric receptor complex
[23]. The type II receptor kinase is constitutively active in the ab-
sence of ligand. BMP type II receptor (BMPR2) has a long C-termi-
nal tail rich in serine and threonine residues [23]. Besides BMPR2,
BMPs can signal also via the activin type II receptors ACVR2A, and
ACVR2B [4,24], which are expressed in various tissues. Whereas
BMPR2 is a speciﬁc receptor for BMPs, ACVR2A and ACVR2B also
can be used by activins, myostatin and nodal. Based on the struc-
tural similarity, BMP type I receptors can be divided into two sub-
groups: activin receptor-like kinase 3 (ALK3, or BMPR-IA) and ALK6
(BMPR-IB) group, and the ALK1 and ALK2 group. While ALK2 and
ALK3/6 are widely expressed in various cell types, ALK1 has a more
selective expression pattern being mainly restricted to endothelial
cells and few other cell types.
A number of BMP co-receptors have been identiﬁed (Fig. 1).
These co-receptors modulate the interactions between BMP li-
gands and receptors. There are two co-receptors, endoglin and
betaglycan, which play important roles in vascular development
and disease, although they lack a signaling domain [25]. Endoglin
and betaglycan can potentiate BMP signaling [26,27]. BMPs can
also bind to the decoy receptor BMP and activin membrane-bound
inhibitor (BAMBI). BAMBI resembles the type I receptors but lacks
an active kinase domain and consequently sequesters ligands from
the active receptors and inhibits BMP signaling [28]. Family mem-
bers of RGM, RGMa, RGMb (DRAGON) and RGMc, were shown to be
implicated in BMP signaling [29–31]. DRAGON was the ﬁrst RGM
family member identiﬁed as a BMP co-receptor [30]. Cell surface
GPI-anchored DRAGON directly binds to BMPs enhancing BMP sig-
naling, but not TGF-b. Moreover, this effect can be reduced by nog-
gin [30]. Interestingly, DRAGON interacted directly with all BMP
type I receptors as well as BMPR2, ActRII and ActRIIB [30]. Further-
more a soluble form of DRAGON fused to Fc (DRAGON-Fc) inhibited
BMP signaling in vitro [30,32]. It is possible that RGM proteins
modulate the ability of cells responding to a low concentration of
BMP ligands by altering the sensitivity of BMPR2 to BMP ligands.
However, the precise mechanism by which RGM proteins regulate
different physiological processes is still not known [33].
4. Smad and non-Smad signaling pathways
After BMP ligand-induced heteromeric complex formation, the
type II receptor kinase phosphorylates the type I receptor. Subse-
quently, the activated type I receptor initiates intracellular signal-
ing by activating the Smad proteins (Fig. 1). Smads can be divided
into three groups: receptor-regulated Smads (R-Smads), inhibitory
Smads (I-Smads), and a common-mediator Smad (i.e. Smad4) [21].
Upon type I receptor-mediated phosphorylation/activation of R-
Smads, they form heteromeric complexes with Smad4. These het-
eromeric R-Smad/Smad4 complexes translocate into the nucleus,
where they regulate target gene expression by directly binding to
Smad-binding elements (SBE), or indirectly through interactions
with DNA-binding transcription factors, and by associating with
co-activators/co-repressors and histone-modifying factors [34].
Inhibitory Smads (I-Smad6 and 7) antagonize BMP and TGF-b
receptor-initiated Smad signaling by mediating the degradation
of receptors and R-Smads. Smad7 inhibits all TGF-b family mem-
bers, while Smad6 is more selective towards BMP family members.
Smad ubiquitin ligases Smurf1 and Smurf2 are recruited by I-
Smads to promote the proteasomal degradation of receptors and
Smads [35–37].Besides canonical BMP receptor/Smad signaling, activated BMP
receptors can initiate non-Smad signaling pathways. MAP kinases
(ERK, JNK and p38 MAPK), phosphoinositide (PI)3 kinase/Akt and
protein kinase C (PKC) signaling pathways, and Rho-GTPases can
also be activated by BMPs and TGF-bs in various cells [38]
(Fig. 1). These non-Smad pathways are also important in creating
diversity and ﬁne-tuning of signals generated by the TGF-b family
ligands [39,40]. Smad-independent pathways can also be involved
in the pathogenesis of vascular diseases, such as pulmonary arte-
rial hypertension (PAH), which will be discussed later.
5. BMP signaling during vessel development
The establishment of the vascular system is an important event
during embryonic development. Neovascularization involves two
mechanisms: ﬁrst the de novo formation of vessels termed vascu-
logenesis, and second, the sprouting and growth of new vessels
from pre-existing ones, known as angiogenesis [41]. Angiogenesis
is a crucial process, which occurs primarily during embryonic
development, and it is almost absent during adulthood besides
wound healing, inﬂammation and the female reproductive cycle.
In healthy tissues, blood vessels are formed by a combination of
several mechanisms, such as sprouting angiogenesis, bone-marrow
derived and/or vascular-wall-resident endothelial progenitor cells
(EPCs) differentiation, and vessel splitting [41]. Main players in
the process of angiogenesis are the endothelial cells (ECs) as well
as smooth muscle cells (SMCs) and pericytes. EC proliferation,
migration and tube formation are critical in the process of angio-
genesis. Sprouting angiogenesis involves the selection of a leading
migrating tip EC that invades the surrounding tissue by extending
numerous ﬁlopodia. VEGF/VEGFR2 signaling triggers single EC to
switch into a tip cell phenotype; these cells thereby express Del-
ta-like 4 (Dll4), a Notch ligand, which instructs neighbor ECs to be-
come so-called stalk cells [42]. Stalk cells trail behind the tip cells
proliferate and form tubes; stalk cell proliferation ensures elonga-
tion of sprouting vessel [43,44]. Ultimately ECs stop proliferating,
acquire a quiescent phenotype and become phalanx ECs. Finally,
the new formed vessel is stabilized by deposition of basement
membrane and recruitment of pericytes/SMCs [45]. Interestingly,
it has been reported that besides ECs, tumor cells can also contrib-
ute to angiogenesis. It has been suggested that cancer cells with
stem cell features can dedifferentiate and acquire an EC-like phe-
notype. These cells can incorporate in the blood vessels and con-
tribute to angiogenesis [41,46].
The role of BMP signaling in vascular development has been
illustrated by studies in knockout animal models [47]. Table 1
(see below and references therein) shows a list of mouse knockout
models for BMP signaling components, including ligands, receptors
and Smads. Genetic deletion or misexpression of different compo-
nents of BMP signaling leads to embryonic death due to cardiovas-
cular malformations and defects in vascular remodeling. Moreover,
proper BMP signaling in both ECs and mural/SMCs has been shown
to be required for appropriate vasculogenesis and angiogenesis.
Interestingly, deletion of the BMP target genes Id1 and Id3 in mice
leads to impaired angiogenesis both in brain and tumor xenografts
[48].
It has been reported that BMP-2, -4, -6 and -7 induce angiogen-
esis, EC proliferation and migration [49,50]. Capillary tube forma-
tion is increased upon activation of the BMP signaling pathway
by overexpression of BMPs or Id1 [51,52]. In contrast, BMP-9 inhib-
its basic ﬁbroblast growth factor (bFGF)-stimulated proliferation
and migration of bovine aortic endothelial cells (BAECs) and blocks
VEGF-induced angiogenesis [36]. BMP-9 has also been reported to
inhibit the migration and growth of human dermal microvascular
ECs [37]. Although (high dose) BMP-9 seems to have inhibitory
Table 1
Deregulated BMP signaling leads to (cardio) vascular abnormalities.
Gene Animal model Human disease References
Bmp-2 KO: Embryonic lethal with defect in cardiac development; Unknown [155,156]
Het: Susceptible to hypoxic pulmonary hypertension associated with reduced endothelial nitric oxide synthase
(eNOS) expression
Bmp-4 Het: Less severe hypoxic pulmonary hypertension and vascular smooth muscle cell proliferation, impaired
vascular remodeling
Unknown [63]
Bmpr2 Het: Pulmonary hypertension PAH [69,70,157,158]
Alk1 KO: Embryonic lethal (E10.5), severe vascular abnormalities; HHT [159–162]
Het: Models HHT type 2; EC conditional KO: Severe vascular malformations mimicking all pathologic features of
HHT.
Alk3 Mesoderm conditional KO: Embryonic lethal (E10.5–E11.5), hemorrhage, impaired vessel remodeling; unknown [163–165]
SMC (embryo): Embryonic lethal (E11) due to vascular and pericardial hemorrhage, impaired vascular
remodeling;
SMC (adult): Impaired vascular remodeling
Endoglin KO: Embryonic lethal (E10.5) due to impaired mature vessel formation; Conditional mutation: AVM HHT [166,167]
Smad1 KO: Embryonic lethal (E9.5) due to defects in allantois formation; with impaired embryonic circulation system Unknown [168]
Smad4 EC conditional KO: Embryonic lethal (E10.5) due to cardiovascular defects HHT (with or without
JP)
[169–171]
Smad5 KO: Embryonic lethal (E9.5–E11.5) due to cardiac and angiogenesis defects Unknown [172,173]
Smad6 KO: Cardiovascular defects, vascular calciﬁcation, hypertension CVM [121,174]
Smad7 KO: Embryonic lethal due to cardiovascular defects Unknown [175]
Smad8 Smad8 mutation mice: Defective pulmonary vascular remodeling PAH [77]
Abbreviations: KO, knockout; het, heterozygous; JP, juvenile polyposis; CVM, congenital cardiovascular malformation.
1996 J. Cai et al. / FEBS Letters 586 (2012) 1993–2002effects on ECs, another report demonstrated that (low dose) BMP-9
induces proliferation of various types of ECs in vitro and promoted
angiogenesis in matrigel plug assays and human pancreatic cancer
xenografts in vivo [53]. It is likely that BMP-9 has disparate effects
on ECs depending on the cellular context and concentration of
BMP-9. The effects of BMPs on ECs can be regulated by various
BMP antagonists and modulators as well. For example, BMPER is
an extracellular matrix protein expressed by ECs, which was
shown to modulate BMP-4 activity in a concentration-dependent
manner, and to exert proangiogenic effects in vascular ECs [54].
Interestingly, MGP gene deletion in mice leads to misregulated
BMP signaling and as a result in arteriovenous malformation
(AVMs) in lungs and kidneys [55]. Thus, selective BMP family
members can stimulate and/or inhibit angiogenesis. Besides,
BMP-induced signaling in ECs response can switch from stimula-
tion to inhibition when co-stimulated with other signals, e.g. Notch
[56]. As mentioned earlier, Notch was shown to have an important
role in stalk cell determination. Recently, Moya et al. reported that
endothelium-speciﬁc inactivation of Smad1/Smad5 in mouse
embryos decreased Notch signaling and increased numbers of tip
cells. In HUVECs downregulation of Smad1/5 reduced the expres-
sion of Notch target genes Hes1 and Hey1, and other stalk cell
speciﬁc transcripts [57], In addition, Larrivée et al. showed that
ALK1-dependent SMAD signaling collaborated with Notch signal
to induce expression of HEY1 and HEY2 in stalk cells, which would
limit the response of stalk cells to VEGF and thus reduce endothe-
lial tip cell formation and sprouting [58].
A lot of research has focused on ECs due to their role in the for-
mation of new vessels. However, research showed that SMCs are
also involved in the maturation of the new-formed vessels, as well
as in vascular diseases. In addition to their effects on EC function,
BMPs were also shown to play key roles in SMC differentiation
and function. BMPs have been shown to inhibit the proliferation
of vascular SMC while enhancing the differentiation of these cells
[59–61]. BMP-2 inhibits the proliferation of cultured rat arterial
SMCs in the presence of serum and injury-induced intimal hyper-
plasia in the in vivo rat carotid artery balloon injury model by
inhibiting SMC proliferation without stimulating extracellular ma-
trix synthesis [61]. BMP-7 inhibits primary human aortic SMC
proliferation in serum-stimulated conditions, as well as
upon induction with platelet-derived growth factor subunit BB(PDGF-BB) and TGF-b1, and maintains the expression of the vascu-
lar SMC phenotype. Furthermore, anti-inﬂammatory activities
have been attributed to BMP-7 suggesting that BMP-7 may play
an important role in maintaining vascular integrity [59,62]. BMP-
4, however, is expressed by ECs in response to hypoxia and it pro-
motes vascular SMC proliferation [63]. It has been demonstrated
that vascular SMCs isolated from different parts of the pulmonary
vasculature have different proliferation responses to BMP-4.
Whereas the proliferation ability of human pulmonary arterial
SMCs isolated from proximal pulmonary arteries is inhibited by
BMP-4, the proliferation of human pulmonary artery SMCs from
peripheral arteries is increased by BMP-4 [64]. In summary, simi-
larly to ECs, the effects of BMPs on vascular SMCs depend on the
source of cells and the culture condition.
6. BMP signaling pathway in vascular diseases
The critical role of BMP signaling in vascular function was fur-
ther corroborated by genetic studies in human [65]. Genetic anal-
ysis revealed that mutations in genes of the BMP signaling or genes
which affect BMP signaling function lead to vascular dysfunction
and disease such as hereditary hemorrhagic telangiectasia (HHT)
and pulmonary arterial hypertension (PAH), vascular calciﬁcation,
and tumor angiogenesis. In addition, disturbance of vascular
homeostasis due to vascular injury, hypertension or atherosclero-
sis was shown to affect the expression of BMPs, thereby suggesting
a role of BMPs in abnormal vascular responses [65].
6.1. Pulmonary arterial hypertension
PAH is a disease characterized by elevated pulmonary artery
pressure leading to heart failure. Processes underlying PAH include
abnormal remodeling of small peripheral vessels in the lung, due to
aberrant proliferation and migration of vascular SMCs, ECs and
ﬁbroblasts [66]. Two types of PAH have been described: sporadic
or idiopathic PAH (IPAH) and hereditary or familial PAH (FPAH).
Heterozygous germ line mutations in BMPR2 are found in more
than 70% of patients with FPAH and 20% of patients with IPAH
[67,68]. Mutations have been found in various regions of BMPR2,
including the ligand-binding domain, the kinase domain, or
the long cytoplasmic tail. Mice expressing a BMPR2 tail domain
J. Cai et al. / FEBS Letters 586 (2012) 1993–2002 1997mutation in pulmonary SMCs develop vascular lesions similar to
PAH [69]. Non-sense mutations in the C-terminal tail of BMPR2
were identiﬁed also in some FPAH patients, suggesting that this re-
gion might play an important role in BMP signaling [67,68]. Het-
erozygous and homozygous BMPR2 deletion speciﬁcally in
pulmonary ECs and pulmonary SMCs mimicked the PAH pheno-
type [69,70]. Endothelial injury and enhanced inﬂammatory re-
sponses may contribute together with BMPR2 heterozygosity to
the development of PAH [71]. Interestingly it was shown that dis-
ruption of BMPR2 expression in PASMCs leads to reduced BMP-2
and BMP-4 signaling, while signaling by BMP-6 and BMP-7 is en-
hanced [72]. It was shown that reduced BMP/Smad signaling re-
sulted in activation of the p38 MAPK pathway, leading to
aberrant PASMC proliferation [64,73,74]. A recent report suggested
that lack of endothelial nitric-oxide synthase (eNOS) due to BMPR2
mutations in pulmonary artery ECs (PAEC) may contribute to the
pathogenesis of PAH. BMP-2 and BMP-4 cannot activate eNOS in
BMPR2 knockdown cell lines or in PAEC from BMPR2 gene muta-
tions patients and inhibition of NOS activity inhibited BMP-2 and
BMP-4 stimulated PAEC migration [75].
Mutations in Smad8 have also been reported in PAH patients
[76]. In addition, loss of Smad8 function in mice results in abnor-
mal vascular remodeling and increased vascular inﬂammation
[77]. It was demonstrated that Smad8 mutation leads to vascular
cell proliferation in HPAH, due to decreased expression of speciﬁc
micro RNAs (miR) miR-21 and miR-27a in pulmonary artery ECs
and pulmonary artery SMCs from tissues of PAH patients [78].
Additionally, overexpression of Smad8 resulted in increased
expression of miRs and reversed the hyper-proliferative phenotype
[78]. Interestingly, certain HHT2 patients develop PPH-like syn-
dromes, suggesting that ALK1 mutations can also be involved in
PPH [79,80]. Moreover alk1+/ mice display increased pulmonary
vascular remodeling which may lead to signs of PAH. This was
shown to be associated with eNOS-dependent reactive oxygen spe-
cies (ROS) production and it could be averted by anti-oxidant treat-
ment [81].
6.2. Hereditary hemorrhagic telangiectasia
Mutations in the ALK1 gene have been reported in some PAH
patients [79]. ALK1 mediates both TGF-b and BMP-9 signaling in
ECs. Interestingly, mutations in ALK1 lead to another vascular dis-
ease related to deregulated BMP signaling, HHT. HHT is an autoso-
mal dominant disease and is associated with telangiectases in skin
and mucosa, frequent epistaxis, and the presence of AVMs in the
lung, liver or brain [82]. HHT type 1 (HHT1) results from patho-
genic mutations in ENG that lead to haploinsufﬁciency of endoglin
[83], while HHT type 2 (HHT2) is caused by loss of function or
dominant negative mutations in ALK1 [84,85]. Interestingly mice
heterozygous for acvrl1 (alk1), tbr1 (alk5), tbr2 and eng develop
vascular abnormalities highly reminiscent of those described in pa-
tients with HHT [25,50]. Several studies have provided evidence
that haploinsufﬁciency of the HHT genes both in ECs and SMCs
leads to abnormal EC proliferation and SMC recruitment. As a re-
sult, vascular abnormalities and fragile leaky vessels occur, to-
gether with the generation of telangiectasias and AVMs [86,87].
In addition, disrupted Notch signaling has been reported to corre-
late with AVMs [88], and ChIP-seq analyses on human umbilical
vein ECs (HUVECs) and pulmonary arterial SMCs pretreated with
BMPs have demonstrated JAG1 as a direct target of Smad1/5 [89].
Another report showed that human polymorphic variants of tyro-
sine-protein phosphatase non-receptor type 14 (PTPN14) inﬂu-
ences the severity of pulmonary arteriovenous malformation
acting via ALK1 and EphrinB2, which suggested that PTPN14 may
also be involve in the pathogenesis of HHT [90].6.3. Atherosclerosis and vascular calciﬁcation
Atherosclerosis is a chronic arterial wall disease that is charac-
terized by chronic inﬂammation and the accumulation of athero-
matous lesions in the inner layer of arteries. BMPs have been
implicated in atherosclerosis progression by regulating endothelial
inﬂammation and cell differentiation. BMP-2 and -4 have been
shown to induce proinﬂammatory effects in the ECs [91,92]. Be-
sides, inhibiting BMP signaling pathway by MGP resulted in re-
duced atherosclerotic lesions formation in apolipoprotein (Apo) E
knockout mice, while enhanced BMP activity led to increased ath-
erosclerotic lesions formation in Apo E knockout mice [91,93]. Ath-
erosclerosis is the most common cause of aortic aneurysms, a
vascular disease which attributes to misregulation of TGF-b signal-
ing [94,95]. However, Jones et al. showed that in 2-week post tho-
racic aortic aneurysms induction mice, the expression level of BMP
signal components and BMP regulators were elevated in mRNA le-
vel, indicating that activation of BMP signaling may also be in-
volved in the pathogenesis of aortic aneurysms [96].
One key histological and clinical event of atherosclerosis is vas-
cular calciﬁcation, which is known as the abnormal deposition of
calcium phosphate salts in blood vessels, myocardium, and cardiac
valves. Vascular calciﬁcation is a tightly regulated process which
leads to differentiation of cells such as SMCs or pericytes into
osteoblast-like cells, and the mineralization of the extracellular
matrix [97]. It is speculated that the course of vascular calciﬁcation
shares many similarities with that of bone mineralization [98].
Pericytes, mesenchymal stem cells, multipotent cells from the
adventitia, resident cells in the media or intima and trans-differen-
tiated SMCs, are the possible cells which transdifferentiate into
osteoblast-like cells in blood vessels [99–102]. It has been sug-
gested that vascular endothelial cells may contribute to osteogenic
differentiation [103]; ECs can transdifferentiate into mesenchymal
stem cells through a process termed endothelial to mesenchymal
transition (EndoMT) [104–106]. Interestingly, in ﬁbrodysplasia
ossiﬁcans progressiva (FOP), a disease characterized by overactive
osteoblasts and ectopic bone formation and linked to a point muta-
tion in BMP type I receptor ALK2 [107], it was shown that ECs can
acquire a progenitor-like phenotype and differentiate into bone
forming osteoblastic cells [103].
BMPs expression is increased at vascular calciﬁcation sites; in
addition BMPs can trigger the differentiation of multipotential cells
into the osteogenic lineage. This raises the possibility that BMPs
may be involved in the process of vascular calciﬁcation [108–
112]. Indeed it was shown that BMPs can direct osteogenic pro-
gramming of vascular mesenchymal progenitors of the pericyte
lineage [110] and that they can promote expression of osteoblast
lineage markers such as alkaline phosphatase in cultured vascular
SMCs [93,97,98,113–115]. Cheng et al. showed that BMP-2 and
the osteoblast homeoproteinMsx2were expressed during the oste-
ogenic process in the aorta of diabetic patients. The BMP-2-Msx2
signaling pathway may enhance vascular calciﬁcation by promot-
ing the differentiation of myoﬁbroblasts into the osteogenic lineage
[116]. In addition BMP-2 enhances the expression of Runx2, a core
transcription factor that is known to regulate osteoblast and chon-
drocyte differentiation and promote vascular SMCs calciﬁcation by
increasing oxidative stress and endoplasmic reticulum (ER) stress
in human coronary artery SMCs. Interestingly, the inhibition of oxi-
dant stress or ER stress reversed this gene expression pattern and
mineralization process [117]. Moreover, recent research showed
that BMPs are involved in vascular calciﬁcation in low-density lipo-
protein (LDL) receptor-deﬁcient (LDLR/) mice. Blockade of BMP
type I receptor function by using either the small molecule inhibitor
LDN-193189 or ALK3-Fc in LDLR/ mice inhibited high-fat diet-
induced vascular inﬂammation as well as osteogenic activity and
1998 J. Cai et al. / FEBS Letters 586 (2012) 1993–2002calciﬁcation, thus suggesting BMP inhibition as a potential treat-
ment for vascular calciﬁcation.
BMP signaling antagonists have been also implicated in vascular
calciﬁcation. Research suggested that MGP might inﬂuence vascu-
lar calciﬁcation by modulating the effect of BMP-2. In C3H10T1/2
cells, MGP overexpression inhibited BMP-2 induced osteogenic
and chondrogenic differentiation, whereas lack of MGP enhanced
these differentiation processes [118]. Notably, it was shown that
transgenic expression of MGP in ApoE/ mice results in dimin-
ished Smad1/5/8 signaling and reduced inﬂammation, lesion for-
mation, and calciﬁcation after fat feeding [93]. On the other hand
MGP deﬁcient ApoE/ mice displayed enhanced Smad1/5/8 sig-
naling and extensive medial calciﬁcation [93]. However, recent re-
search showed that MGP can inhibit calciﬁcation in a BMP-2
independent manner in intact vessels and lack of GlaMGP (carbox-
ylated MGP) was not the reason for medial calciﬁcation in rat renal
failure model [119].
As mentioned earlier the inhibitory Smad6 interferes speciﬁ-
cally with the BMP pathway. Interestingly, perturbation of Smad6
expression was found to be associated with calciﬁcation of the aor-
tic valve. In human aortic valve (AV), high levels of BMP antago-
nists (noggin and CV-2/BMPER) and Smad6 were detected in the
ventricular endothelium, while low levels of such inhibitors were
found in the ﬁbrosa endothelium. This uneven distribution was
shown to be responsible for the side-dependent calciﬁcation of hu-
man AVs [120]. In addition, mutations in the Smad6 gene were
found to predispose to congenital cardiovascular malformation.
The capacity of Smad6 to inhibit BMP-induced osteogenic differen-
tiation was signiﬁcantly decreased by a C484F mutation in Smad6
[121]. Thus, BMPs may be important in the pathology of vascular
calciﬁcation, even though deﬁnitive evidence supporting this is
still lacking.
6.4. Tumor angiogenesis
Tumor growth beyond 2–3 mm in size makes diffusion insufﬁ-
cient to supply tumor cells with oxygen and nutrients and for the
removal of the waste products [122]. Angiogenesis, i.e. the forma-
tion of new blood vessels from pre-existing ones, is then needed for
the tumors to grow. In addition, blood vessels provide the main
route for metastatic spread [122]. Several inhibitors of angiogene-
sis, such as bevacizumab (monoclonal antibody targeting VEGF)
and sorafenib and sunitinib (tyrosine kinase inhibitors) have been
used for the treatment of solid tumors [123,124].
BMPs have been found misexpressed in gastric, ovarian, pros-
tate, pancreatic breast, lung and colon tumors [125–131]. BMP-2
and BMP-4 were shown to favor angiogenesis by stimulating the
secretion of pro-angiogenic growth factors, such as VEGF
[52,132]. In the case of lung cancer, BMP-2 is highly expressed in
the majority of patient-derived lung carcinomas [133] and recom-
binant BMP-2 potently increases the size and number of blood ves-
sels in tumors formed by A549 cells in nude mice [134]. Moreover,
either recombinant noggin or an anti-BMP-2 antibody could inhibit
the activity of BMP-2, resulting in a signiﬁcant reduction in tumor
growth [133]. Besides BMP-2, other BMPs have also been reported
to be involved in tumor angiogenesis. Rothhammer et al. showed
that BMP-2 and BMP-4 are highly expressed in malignant melano-
mas, and they promoted cell invasion and migration of microvas-
cular endothelial cells. Moreover, ECs have a reduced tube
formation capacity when BMPs activities were inhibited [135].
BMP antagonist chordin has been reported to inhibit in vitro
BMP-4 induced tube formation in malignant melanoma cells [135].
ALK1, a type I receptor for TGF-b, BMP-9 and BMP-10 have re-
ceived a lot of attention recently as an anti-angiogenesis target. A
recent study indicated that ALK1 is widely expressed on prostate,
skin, thyroid, kidney, ovary, lung, pancreas, and liver tumor bloodvessels [136,137]. ALK1 is mainly expressed in developing arterial
endothelial cells and is greatly reduced in adult arteries. However,
ALK1 expression can be induced during tumor angiogenesis
[137,138]. It has been suggested that ALK1 signaling and function
in ECs may depend on multiple proangiogenic factors (including
VEGF and bFGF), and BMP-9-induced (tumor) angiogenesis can
be speciﬁcally inhibited by an ALK1 antibody (anti-ALK1) [136].
Besides, anti-ALK1 can decrease tumor growth and angiogenesis
when combined with VEGF receptor inhibitor in human/mouse
chimera tumor model [136]. Other research described that a solu-
ble chimeric protein (ALK1-Fc) which serves as BMP-9 (and -10) li-
gand trap, can inhibit (tumor) angiogenesis by interfering with
ALK1 signaling both in vitro and in vivo [137,139]. Therefore, tar-
geting ALK1 may effectively inhibit tumor angiogenesis and it is
therefore a promising therapeutic strategy for cancer patients.
Endoglin plays a crucial role in EC function. Studies in mice re-
vealed that tumor growth and angiogenesis is reduced in endog-
lin-haploinsufﬁcient mice [140]. In addition endoglin neutralizing
antibodies have been used for vascular targeting and it was shown
that they can inhibit both endothelial cell proliferation and tumor
growth inmouse cancermodels [25]. It is known that a soluble form
of endoglin (sol Eng) contributes to the pathogenesis of preeclamp-
sia [25]. Research showed that a fusion protein, which combined
the endoglin extracellular domain (ECD) and immunoglobulin Fc
domain, can signiﬁcantly reduce VEGF induced angiogenesis
in vitro and ex vivo [141], presumably by speciﬁcally binding to
pro-angiogenic BMP-9 with a high afﬁnity. These results suggest
that endoglin-Fc may be used as a potential anti-angiogenesis ther-
apeutic agent [142]. Since the process of angiogenesis is tightly reg-
ulated by BMPs, a further understanding of their molecular
mechanisms will provide opportunities for better diagnosis and
development of new therapies targeting angiogenesis, tumor
growth, and metastatic spread of disease.7. Conclusions and perspective
BMP signaling plays a crucial role in cardiovascular homeostasis
and disease. Genetic studies in mice indicate that components of
BMP signaling are involved in EC and SMC interactions, EC function
and angiogenesis. The knowledge regarding the role of BMP signal-
ing in vascular diseases and cancer has mainly come from mouse
models and clinical investigations. However, deﬁnitive evidences
from functional studies in human tissues are still rare. Genetic
mouse model studies showed that BMP function might depend
on cell type and environment, but the availability of human tissues
and the limited life span of patient-derived somatic cells limit the
development of this research area. The use of induced pluripotent
stem cells (iPSCs) technology could help to overcome these limita-
tions [143–145]. Generated iPSCs from human skin ﬁbroblasts,
keratinocytes, adipose stem cells and lymphocytes [146–148],
can be differentiated into various cell types [149], including ECs
and SMCs [150]. It is possible to utilize this new technology to gen-
erate ECs and SMCs from patients with vascular disorders (and
from healthy volunteers) in order to investigate the pathology of
vascular diseases and perhaps transplant cells to cure patients
[151], or perform screens to identify small chemical compounds
to rescue disease phenotypes. Of interest, the BMP receptor antag-
onist dorsomorphin and its more selective derivative LDN-193189
have recently been reported to inhibit BMP signaling [152,153]. Yu
et al. found that dorsomorphin selectively inhibited the BMP type I
receptors ALK2, ALK3 and ALK6 and blocked BMP-mediated
SMAD1/5/8 phosphorylation [152]. In addition, an optimized com-
pound (LDN-193189 or DM-3189) with higher activity and speci-
ﬁcity for BMP type I receptors has been developed from a
structure–activity relationship study on dorsomorphin [153]. The
J. Cai et al. / FEBS Letters 586 (2012) 1993–2002 1999ongoing development of small molecule inhibitors/activators of
BMP signaling will offer new opportunities for manipulating BMP
signaling in therapeutic means. This will beneﬁt future therapy
of BMP related diseases caused by insufﬁcient BMP signaling, such
as PAH and overactive BMP signaling, such as tumor angiogenesis
and FOP [154].
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